ARTÍCULOS-tratamiento

NOTA: En esta sección se recogen únicamente artículos elaborados por autores españoles o pertenecientes a instituciones españolas.

.General

  1. Rivera-Izquierdo M, et al. Agentes terapéuticos utilizados en 238 pacientes hospitalizados por COVID-19 y su relación con la mortalidad. Med Clin (Barc). 2020 Nov 13;155(9):375-381 [doi
  2. Gonzalez-Zorn B. Antibiotic use in the COVID-19 crisis in Spain. Clin Microbiol Infect. 2021 Apr;27(4):646-647 [doi]
  3. Rodríguez-Molinero A, et al. Association between COVID-19 prognosis and disease presentation, comorbidities and chronic treatment of hospitalized patients. PLoS One. 2020 Oct 15;15(10):e0239571 [doi
  4. Duarte-Salles T, et al. Baseline characteristics, management, and outcomes of 55,270 children and adolescents diagnosed with COVID-19 and 1,952,693 with influenza in France, Germany, Spain, South Korea and the United States: an international network cohort study. medRxiv [Preprint]. 2020 Oct 30:2020.10.29.20222083 [doi
  5. Poblador-Plou B, et al. Baseline Chronic Comorbidity and Mortality in Laboratory-Confirmed COVID-19 Cases: Results from the PRECOVID Study in Spain. Int J Environ Res Public Health. 2020 Jul 17;17(14):5171 [doi
  6. Jiménez E, et al. Characteristics, complications and outcomes among 1549 patients hospitalised with COVID-19 in a secondary hospital in Madrid, Spain: a retrospective case series study. BMJ Open. 2020 Nov 10;10(11):e042398 [doi]
  7. Tan EH, et al. Characteristics, outcomes, and mortality amongst 133,589 patients with prevalent autoimmune diseases diagnosed with, and 48,418 hospitalised for COVID-19: a multinational distributed network cohort analysis. medRxiv [Preprint]. 2020 Nov 27:2020.11.24.20236802 [doi
  8. Berenguer J, et al. Characteristics and predictors of death among 4,035 consecutively hospitalized patients with COVID-19 in Spain. Clin Microbiol Infect. 2020 Aug 4;S1198-743X(20)30431-6 [doi
  9. Markewitz R, et al. Clinical correlates of anti-SARS-CoV-2 antibody profiles in Spanish COVID-19 patients from a high incidence region. Sci Rep. 2021 Feb 23;11(1):4363 [doi
  10. Quintana-Díaz M, et al. Coagulation Parameters: An Efficient Measure for Predicting the Prognosis and Clinical Management of Patients with COVID-19. J Clin Med. 2020 Oct 28;9(11):3482 [doi
  11. Borobia AM, et al. A Cohort of Patients with COVID-19 in a Major Teaching Hospital in Europe. J Clin Med. 2020;9(6):1733 [doi
  12. Martos Pérez F, et al. Comorbilidad y factores pronósticos al ingreso en una cohorte COVID-19 de un hospital general. Rev Clin Esp. 2020 Jun 26;S0014-2565(20)30179-X [doi
  13. Huttner B, et al. COVID-19: don’t neglect antimicrobial stewardship principles! Clin Microbiol Infect. 2020 Apr 29;S1198-743X(20)30232-9 [doi]
  14. Rodriguez-Gonzalez CG, et al. COVID-19 in hospitalised patients in Spain: a cohort study in Madrid. Int J Antimicrob Agents. 2021 Feb;57(2):106249 [doi
  15. López Reboiro ML, et al. COVID-19 y Argumentum ad ignorantiam o «no todo vale». Rev Clin Esp. 2020 May 4;10.1016/j.rce.2020.04.013 [doi]
  16. Burn E, et al. Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study. Nat Commun. 2020 Oct 6;11(1):5009 [doi
  17. Pérez-Belmonte LM, et al. Differences between Clinical Protocols for the Treatment of Coronavirus Disease 2019 (COVID-19) in Andalusia, Spain. Int J Environ Res Public Health. 2020 Sep 19;17(18):6845 [doi
  18. Andrade-Campos M, et al. Direct and indirect effects of the SARS-CoV-2 pandemic on Gaucher Disease patients in Spain: Time to reconsider home-based therapies? Blood Cells Mol Dis. 2020 Jul 14;85:102478 [doi
  19. Cantudo-Cuenca MD, et al. Drug-drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain. Sci Rep. 2021 Jun 14;11(1):12414 [doi
  20. Marta-Enguita J, et al. Factores de riesgo y predictores de gravedad en pacientes hospitalizados por COVID-19: análisis de 52 casos. Med Clin (Barc). 2020 Jun 25;S0025-7753(20)30401-2 [doi
  21. Prieto-Alhambra D, et al. Filling the gaps in the characterization of the clinical management of COVID-19: 30-day hospital admission and fatality rates in a cohort of 118 150 cases diagnosed in outpatient settings in Spain. Int J Epidemiol. 2021 Jan 23;49(6):1930-1939 [doi
  22. Muñoz P, et al. The first 100 cases of COVID-19 in a Hospital in Madrid with a 2-month follow-up. Rev Esp Quimioter. 2020 Oct;33(5):369-378 [doi
  23. Viana-Llamas MC, et al. Hypoalbuminemia on admission in COVID-19 infection: An early predictor of mortality and adverse events. A retrospective observational study. Med Clin (Barc). 2021 Jan 28:S0025-7753(21)00032-4 [doi
  24. Valdivia-Mazeyra MF, et al. Increased number of pulmonary megakaryocytes in COVID-19 patients with diffuse alveolar damage: an autopsy study with clinical correlation and review of the literature. Virchows Arch. 2021 Mar;478(3):487-496n [doi
  25. Evangelidis N, et al. International Survey to Establish Prioritized Outcomes for Trials in People With Coronavirus Disease 2019.Crit Care Med. 2020 Nov;48(11):1612-1621 [doi
  26. De la Rica R, et al. Low Albumin Levels Are Associated with Poorer Outcomes in a Case Series of COVID-19 Patients in Spain: A Retrospective Cohort Study. Microorganisms. 2020 Jul 24;8(8):E1106 [doi]
  27. Núñez-Gil IJ, et al. Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry. Intern Emerg Med. 2020 Nov 9:1–10 [doi
  28. Parzych E, et al. Nucleic Acid Approaches to Antibody-based Therapeutics for COVID-19: A Perspective. J Allergy Clin Immunol. 2020 Jul 2;S0091-6749(20)30951-9 [doi
  29. Alcántara Montero A, et al. Posibles factores protectores de la infección por SARS-CoV-2 en una paciente vulnerable: a propósito de un caso. Semergen. 2020 Jun 5;S1138-3593(20)30191-X [doi
  30. Rubio-Rivas M, et al. Predicting Clinical Outcome with Phenotypic Clusters in COVID-19 Pneumonia: An Analysis of 12,066 Hospitalized Patients from the Spanish Registry SEMI-COVID-19. J Clin Med. 2020 Oct 29;9(11):3488 [doi
  31. Álvarez Nonay A, et al. Prescription profile of medication in patients with SARS-CoV-2 infection hospitalized in Aragón, Spain. Med Clin (Barc). 2021 Jan 22;156(2):88-89 [doi
  32. Sisó-Almirall A, et al. Prognostic factors in Spanish COVID-19 patients: A case series from Barcelona. PLoS One. 2020 Aug 21;15(8):e0237960 [doi
  33. Jimeno S, et al. Prognostic implications of neutrophil-lymphocyte ratio in COVID-19. Eur J Clin Invest. 2021 Jan;51(1):e13404 [doi
  34. Teigell Muñoz FJ, et al. A safe protocol to identify low-risk patients with COVID-19 pneumonia for outpatient management. Intern Emerg Med. 2021 Feb 23 [doi
  35. Reina J. El SARS-CoV-2, una nueva zoonosis pandémica que amenaza al mundoVacunas. 2020;21(1):17-22 [doi
  36. Bosch-Barrera J, et al. Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients. J Clin Med. 2020;9(6):1770 [doi
  37. Baldassarri M, et al. Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males. EBioMedicine. 2021 Feb 26;65:103246 [doi
  38. Rivera-Izquierdo M, et al. Sociodemographic, clinical and laboratory factors on admission associated with COVID-19 mortality in hospitalized patients: A retrospective observational study. PLoS One. 2020 Jun 25;15(6):e0235107 [doi
  39. Rivera-Izquierdo M, et al. Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality. Med Clin (Engl Ed). 2020 Nov 13;155(9):375-381 [doi
  40. De Medrano VAL, et al. Tomar o no tomar «decisiones en caliente» respecto al tratamiento de la infección por SARS-CoV-2 [texto completo]. Rev Clin Esp. 2020 Apr 15 [doi]  
  41. Corral Gudino L. El tratamiento de la pandemia por COVID 19. Ante la expectativa de evitar una oportunidad perdida [texto completo]. Rev Clin Esp. 2020 Apr 15 [doi
  42. Ye Z, et al. Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence-based guideline. CMAJ. 2020;192(20):E536-E545 [doi

Alergología

  1. Barroso B, et al. Presenting prevalence, characteristics and outcome of asthmatic patients with T2 diseases in hospitalized subjects with COVID-19 in Madrid, Spain. J Investig Allergol Clin Immunol. 2020;0 [doi]

Anestesiología

  1. Tavernier E, et al. Awake prone positioning of hypoxaemic patients with COVID-19: protocol for a randomised controlled open-label superiority meta-trial. BMJ Open. 2020 Nov 11;10(11):e041520 [doi]
  2. Tusman G, et al. COVID-19: cómo transformar un ventilador de no invasiva en un ventilador de críticos. Rev Esp Anestesiol Reanim. 2020;S0034-9356(20)30117-1 [doi
  3. Taboada M, et al. Critically ill COVID-19 patients attended by anesthesiologists in northwestern Spain: a multicenter prospective observational study. Rev Esp Anestesiol Reanim. 2021 Jan;68(1):10-20 [doi
  4. Tornero C, et al. A prospective, randomized, controlled study assessing vagus nerve stimulation using the gammaCore®-Sapphire device for patients with moderate to severe CoViD-19 Respiratory Symptoms (SAVIOR): A structured summary of a study protocol for a randomised controlled trial”. Trials. 2020 Jun 26;21(1):576 [doi
  5. Cinesi Gómez C, et al. Recomendaciones de consenso respecto al soporte respiratorio no invasivo en el paciente adulto con insuficiencia respiratoria aguda secundaria a infección por SARS-CoV-2. Rev Esp Anestesiol Reanim. 2020;67(5):261-270 [doi
  6. Hernández A, et al. Two known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19 [texto completo]. Rev Esp Anestesiol Reanim. 2020 Apr 14:S0034-9356(20)30075-X [doi]

Aparato digestivo

  1. Benedé-Ubieto R, et al. Abnormal Liver Function Test in Patients Infected with Coronavirus (SARS-CoV-2): A Retrospective Single-Center Study from Spain. J Clin Med. 2021 Mar 3;10(5):1039 [doi
  2. Rodríguez-Lago I, et al. Characteristics and Prognosis of Patients With Inflammatory Bowel Disease During the SARS-CoV-2 Pandemic in the Basque Country (Spain). Gastroenterology. 2020 Aug;159(2):781-783 [doi
  3. Colmenero J, et al. Epidemiological pattern, incidence and outcomes of COVID-19 in liver transplant patients. J Hepatol. 2020 Aug 1;S0168-8278(20)30521-3 [doi
  4. Guerra I, et al. Incidence, Clinical Characteristics, and Evolution of SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: A Single-Center Study in Madrid, Spain. Inflamm Bowel Dis. 2021 Jan 1;27(1):25-33 [doi
  5. Lens S, et al. SARS-CoV-2 in patients on antiviral HBV and HCV therapy in Spain. J Hepatol. 2020 Nov;73(5):1262-1263 [doi

Atención primaria

  1. Morán Blanco JI, et al. Antihistamines and azithromycin as a treatment for COVID-19 on primary health care – A retrospective observational study in elderly patients. Pulm Pharmacol Ther. 2021 Apr;67:101989 [doi
  2. Vila-Córcoles A, et al. Influence of prior comorbidities and chronic medications use on the risk of COVID-19 in adults: a population-based cohort study in Tarragona, Spain. BMJ Open. 2020 Dec 10;10(12):e041577 [doi

Cardiología

  1. Jiménez Hernández S, et al. Características clínicas, factores de riesgo y resultados finales de pacientes con COVID-19 diagnosticados de tromboembolia de pulmón en urgencias. Emergencias. 2020;32(4):253-257
  2. Hamadeh A, et al. Characteristics and Outcomes in Patients Presenting With COVID-19 and ST-Segment Elevation Myocardial Infarction. Am J Cardiol. 2020 Sep 15;131:1-6 [doi
  3. Soria Arcos F, et al. Controversias sobre el tratamiento con IECA/ARA-II y Covid-19 [texto completo]. Rev Esp Cardiol. 2020 Apr 10;10.1016/j.recesp.2020.03.014 [doi
  4. Eiras S, et al. COVID-19 and treatment guided by biochemical and molecular diagnostic tests to reduce myocardial damage and cardiotoxicity [texto completo]. Rev Esp Cardiol (Engl Ed). 2020;73(8):691-693 [doi]
  5. Gonzalez-Fernandez O, et al. D-dimer and right ventricular abnormalities as prognostic factors in critically ill COVID-19 patients. Rev Esp Cardiol (Engl Ed). 2020 Jul 16;73(11):966–8 [doi
  6. García-Rodríguez D, et al. Drug-induced QT prolongation in COVID-19 pneumonia: influence on in-hospital survival. Rev Esp Cardiol (Engl Ed). 2021 Jan;74(1):111-112 [doi]
  7. Rodríguez-Santamarta M, et al. Echocardiographic findings in critical patients with COVID-19. Rev Esp Cardiol (Engl Ed). 2020 Oct;73(10):861-863 [doi
  8. Torres González N, et al. Electrocardiographic/QT interval monitoring with a portable device in hospitalized patients with COVID-19: a protocol proposal [published online ahead of print, 2020 Jun 25]. Rev Esp Cardiol (Engl Ed). 2020 Jun 25;S1885-5857(20)30278-4 [doi]
  9. Solano-López J, et al. Factores de riesgo de muerte hospitalaria en pacientes con infarto agudo de miocardio durante la pandemia de la COVID-19. Rev Esp Cardiol. 2020 Dec;73(12):985-993 [doi
  10. Uribarri A, et al. Fibrilación auricular en pacientes con COVID-19. Utilidad de la puntuación CHA2DS2-VASc: un análisis del registro internacional HOPE COVID-19. Rev Esp Cardiol. 2021 Mar 2 [doi
  11. Bardají A, et al. Implicaciones pronósticas del daño miocárdico en pacientes con y sin diagnóstico confirmado de COVID-19 atendidos en un hospital universitario. Rev Esp Cardiol. 2021 Jan;74(1):24-32 [doi
  12. Calvo-Fernández A, et al. Marcadores de daño miocárdico en la predicción del pronóstico a corto plazo de los pacientes con COVID-19. Rev Esp Cardiol (Engl Ed). 2021 Jul;74(7):576-583 [doi
  13. Oyarzabal L, et al. Neurohormonal treatment in tako-tsubo cardiomyopathy precipitated by COVID-19. Response. Rev Esp Cardiol (Engl Ed). 2021 Feb;74(2):201 [doi]
  14. Bardají A, et al. Prognostic implications of myocardial injury in patients with and without COVID-19 infection treated in a university hospital. Rev Esp Cardiol (Engl Ed). 2021 Jan;74(1):24-32 [doi
  15. Vivas D, et al. Recomendaciones sobre el tratamiento antitrombótico durante la pandemia COVID-19. Posicionamiento del Grupo de Trabajo de Trombosis Cardiovascular de la Sociedad Española de Cardiología [texto completo]. Rev Esp Cardiol. 2020 Apr 22 [doi
  16. Vivas D, et al. Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology. Rev Esp Cardiol (Engl Ed). 2020 Jun 19;S1885-5857(20)30272-3 [doi]
  17. Moreno G, et al. Revisión sistemática sobre la utilidad pronóstica del dímero-D, coagulación intravascular diseminada y tratamiento anticoagulante en pacientes graves con COVID-19. Med Intensiva. 2020 Jun 17;S0210-5691(20)30187-X [doi]
  18. Lorca R, Triviño RL, Morís C. Tratamiento de pacientes de cardio-onco-hematología durante la pandemia actual por COVID-19. Rev Esp Cardiol. 2020 May 11;10.1016/j.recesp.2020.05.002 [doi]
  19. Frías Vargas M, et al. Tratamiento hipolipemiante en la era COVID-19. Semergen. 2020 Oct;46(7):497-502 [doi
  20. Oyarzabal L, et al. Tratamiento neurohormonal en miocardiopatía de tako-tsubo precipitada por COVID-19. Respuesta. Rev Esp Cardiol. 2021 Feb;74(2):201 [doi

Cirugía

  1. Ielpo B, et al. National survey on the treatment of cholelitiasis in Spain during the initial period of the COVID-19 pandemic. Cir Esp (Engl Ed). 2021 May;99(5):346-353 [doi]
  2. Montero Feijoo A, et al. Recomendaciones prácticas para el manejo perioperatorio del paciente con sospecha o infección grave por coronavirus SARS-CoV-2. Rev Esp Anestesiol Reanim. 2020;S0034-9356(20)30053-0 [doi]
  3. Giménez Francés C, et al. Response to «National survey on the treatment of acute appendicitis in Spain during the initial period of the COVID-19 pandemic». Cir Esp (Engl Ed). 2021 Feb;99(2):168-169 [doi]

Cirugía cardíaca

  1. Pérez de la Sota E, et al. ECMO-Challenges, strategies, and preparation from Spain. J Card Surg. 2020 Aug 26:10.1111/jocs.14980 [doi]

Cuidados intensivos

  1. Ramírez P, et al. Acute respiratory distress syndrome due to COVID-19. Clinical and prognostic features from a medical Critical Care Unit in Valencia, Spain. Med Intensiva. 2021 Jan-Feb;45(1):27-34 [doi
  2. Lorente L, et al. Association between red blood cell distribution width and mortality of COVID-19 patients. Anaesth Crit Care Pain Med. 2021 Feb;40(1):100777 [doi]
  3. Ferrando C, et al. Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS. Intensive Care Med. 2020 Dec;46(12):2200-2211 [doi
  4. Miró Ò, et al. Comparison of the demographic characteristics and comorbidities of patients with COVID-19 who died in Spanish hospitals based on whether they were or were not admitted to an intensive care unit. Med Intensiva. 2021 Jan-Feb;45(1):14-26 [doi
  5. Pérez Acosta G, et al. Consensus document on tracheotomy in patients with COVID 19. Med Intensiva (Engl Ed). 2021 May;45(4):253-254 [doi
  6. Martín Delgado MC, et al. Respuesta a «Documento de consenso de la traqueotomía en pacientes con COVID-19». Med Intensiva (Engl Ed). 2021 May;45(4):254-255 [doi
  7. Yankah CA, et al. COVID-19 Pulmonary Failure and Extracorporeal Membrane Oxygenation: First Experience from Three European Extracorporeal Membrane Oxygenation Centers. Thorac Cardiovasc Surg. 2021 Apr;69(3):259-262 [doi]
  8. Belenguer-Muncharaz A, et al. Fracaso de la ventilación no invasiva tras empleo de oxigenoterapia de alto flujo en pacientes con neumonía por SARS-CoV-2. Med Intensiva. 2020 Jul 9;S0210-5691(20)30220-5 [doi
  9. Lorente L, et al. HLA genetic polymorphisms and prognosis of patients with COVID-19. Med Intensiva. 2021 Mar;45(2):96-103 [doi
  10. González Cortés R, et al. A multicenter national survey of children with SARS-CoV-2 infection admitted to Spanish Pediatric Intensive Care Units. Intensive Care Med. 2020;1-3 [doi
  11. Ferrando C, et al. Patient characteristics, clinical course and factors associated to ICU mortality in critically ill patients infected with SARS-CoV-2 in Spain: A prospective, cohort, multicentre study. Rev Esp Anestesiol Reanim. 2020 Oct;67(8):425-437 [doi
  12. Díaz E, et al. Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH). Med Intensiva. 2021 Mar;45(2):104-121 [doi
  13. Estella Á, et al. Predictive factors of six-week mortality in critically ill patients with SARS-CoV-2: A multicenter prospective study. Med Intensiva (Engl Ed). 2021 Mar 8:S0210-5691(21)00033-4 [doi
  14. Tornero C, et al. A prospective, randomized, controlled study assessing vagus nerve stimulation using the gammaCore®-Sapphire device for patients with moderate to severe CoViD-19 Respiratory Symptoms (SAVIOR): A structured summary of a study protocol for a randomised controlled trial”. Trials. 2020;21(1):576 [doi
  15. Rodríguez A, et al. Severe infection due to the SARS-CoV-2 coronavirus: Experience of a tertiary hospital with COVID-19 patients during the 2020 pandemic. Med Intensiva. 2020 Dec;44(9):525-533 [doi
  16. Zuazua González A, Collazo Lorduy T, Coello Casariego G, Collazo Lorduy A, León Soriano E, Torralba Morón A, et al. Surgical Tracheostomies in COVID-19 Patients: Indications, Technique, and Results in a Second-Level Spanish Hospital. OTO Open. 2020 Sep 15;4(3):2473974X20957636 [doi
  17. Moreno G, et al. Systematic review of the prognostic utility of D-dimer, disseminated intravascular coagulation, and anticoagulant therapy in COVID-19 critically ill patients. Med Intensiva. 2021 Jan-Feb;45(1):42-55 [doi
  18. González-Castro A, et al. Ventilación mecánica no invasiva y oxigenoterapia de alto flujo en la pandemia COVID-19: El valor de un empate. Med Intensiva. 2021 Jun-Jul;45(5):320-321 [doi

Dermatología

  1. Andina D, et al. Chilblains in children in the setting of COVID-19 pandemic. Pediatr Dermatol. 2020;37(3):406-411 [doi
  2. Fulgencio-Barbarin J, et al. COVID-19 and systemic therapies in psoriasis: experience of a tertiary hospital in Madrid. Int J Dermatol. 2020 Nov;59(11):1425-1426 [doi
  3. Queiro Silva R, et al. COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in North Spain. Dermatol Ther. 2020 Nov;33(6):e13961 [doi
  4. Pastor Nieto MA, et al. Prior treatment with immunosuppressants among COVID-19 inpatients at one hospital in Spain. J Eur Acad Dermatol Venereol. 2020 Dec;34(12):e760-e762 [doi

Endocrinología

  1. Fresán U, et al. Independent Role of Severe Obesity as a Risk Factor for COVID-19 Hospitalization: A Spanish Population-Based Cohort Study. Obesity (Silver Spring). 2021 Jan;29(1):29-37 [doi
  2. Frías Vargas M, et al. Tratamiento hipolipemiante en la era COVID-19. Semergen. 2020 Jul 1;S1138-3593(20)30206-9 [doi

Fisioterapia

  1. Torres-Castro R, et al. Functional Limitations Post-COVID-19: A Comprehensive Assessment Strategy. Arch Bronconeumol. 2021 Jan;57 Suppl 1:7-8 [doi

Geriatría

  1. Mostaza JM, et al. Clinical course and prognostic factors of COVID-19 infection in an elderly hospitalized population. Arch Gerontol Geriatr. 2020 Jul 27;91:104204 [doi
  2. Águila-Gordo D, et al. Mortalidad y factores pronósticos asociados en pacientes ancianos y muy ancianos hospitalizados con infección respiratoria COVID-19. Rev Esp Geriatr Gerontol. 2020 Nov 11:S0211-139X(20)30174-8 [doi
  3. Segrelles-Calvo G, et al. Therapeutic Limitation in Elderly Patients: Reflections Regarding COVID19. Arch Bronconeumol (Engl Ed). 2020 Oct;56(10):677-679 [doi
  4. Callejas Rubio JL, et al. Tratamiento y evolución del síndrome de tormenta de citoquinas asociados a infección por SARS-CoV-2 en pacientes octogenarios. Rev Esp Geriatr Gerontol. 2020;S0211-139X(20)30063-9 [doi
  5. Gutiérrez Rodríguez J, et al. Variables asociadas con mortalidad en una población de pacientes mayores de 80 años y con algún grado de dependencia funcional, hospitalizados por COVID-19 en un Servicio de Geriatría. Rev Esp Geriatr Gerontol. 2020 2020 Nov-Dec;55(6):317-325
  6. Ortonobes Roig S, et al. Variables clínicas y farmacológicas de pacientes nonagenarios hospitalizados por COVID-19. Rev Esp Quimioter. 2021 Apr;34(2):145-150 [doi

Hematología

  1. van Doesum J, et al. Clinical characteristics and outcome of SARS-CoV-2-infected patients with haematological diseases: a retrospective case study in four hospitals in Italy, Spain and the Netherlands. Leukemia. 2020 Sep;34(9):2536-2538 [doi
  2. Andrade-Campos M, et al. Direct and indirect effects of the SARS-CoV-2 pandemic on Gaucher Disease patients in Spain: Time to reconsider home-based therapies? Blood Cells Mol Dis. 2020 Nov;85:102478 [doi
  3. Zalba Marcos S, et al. Infection and thrombosis associated with COVID-19: Possible role of the ABO blood group. Med Clin (Barc). 2020 Oct 23;155(8):340-343 [doi]
  4. Faura A, et al. Initial report on Spanish pediatric oncologic, hematologic, and post stem cell transplantation patients during SARS-CoV-2 pandemic. Pediatr Blood Cancer. 2020 Sep;67(9):e28557 [doi
  5. Regalado-Artamendi I, et al. Risk Factors and Mortality of COVID-19 in Patients With Lymphoma: A Multicenter Study. Hemasphere. 2021 Feb 10;5(3):e538 [doi
  6. Piñana JL, et al. Risk factors and outcome of COVID-19 in patients with hematological malignancies. Exp Hematol Oncol. 2020 Aug 25;9:21 [doi

Inmunología

  1. Laguna-Goya R, et al. IL-6-based mortality risk model for hospitalized patients with COVID-19. J Allergy Clin Immunol. 2020 Oct;146(4):799-807.e9 [doi

Medicina interna

  1. Carrasco-Sánchez FJ, et al. Admission hyperglycaemia as a predictor of mortality in patients hospitalized with COVID-19 regardless of diabetes status: data from the Spanish SEMI-COVID-19 Registry. Ann Med. 2021 Dec;53(1):103-116 [doi
  2. Rodilla E, et al. Association of Hypertension with All-Cause Mortality among Hospitalized Patients with COVID-19. J Clin Med. 2020 Sep 28;9(10):3136 [doi
  3. Vizcarra P, et al. Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort. Lancet HIV. 2020 Aug;7(8):e554-e564 [doi
  4. Parra LM, et al. Hospital Readmissions of Discharged Patients with COVID-19. Int J Gen Med. 2020 Dec 2;13:1359-1366 [doi]
  5. Del Amo J, et al. Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy : A Cohort Study. Ann Intern Med. 2020 Oct 6;173(7):536-541 [doi
  6. Carretero Gómez J, et al. La inflamación, la desnutrición y la infección por SARS-CoV-2: una combinación nefasta. Rev Clin Esp. 2020 Nov;220(8):511-517 [doi
  7. Iftimie S, et al. Risk factors associated with mortality in hospitalized patients with SARS-CoV-2 infection. A prospective, longitudinal, unicenter study in Reus, Spain. PLoS One. 2020 Sep 3;15(9):e0234452 [doi
  8. Marta-Enguita J, et al. Risk factors and severity predictors in COVID-19 hospitalized patients: Analysis of 52 patients. Med Clin (Barc). 2020 Oct 23;155(8):360-361 [doi

Medicina nuclear

  1. Frantellizzi V, et al. Manejo de pacientes con CPRCm tratados con dicloruro de radio-223 en el escenario del brote de COVID-19. Rev Esp Med Nucl Imagen Mol. 2020 Nov-Dec;39(6):391-392 [doi

Nefrología

  1. Florit EA, et al. ¿Es la hiporrespuesta inmune de la uremia un factor de protección contra la neumonía grave por COVID-19? Nefrologia. 2020 May 23;S0211-6995(20)30064-3 [doi]
  2. Sánchez Cadena AD, et al. Intravenous immunoglobulins: A therapeutic alternative to consider in kidney transplant patients with COVID-19. Nefrologia. 2020 May 25;41(2):220–2 [doi
  3. Lamas Barreiro JM, et al. Supresión de angiotensina II en la infección por el virus SARS-CoV-2: una propuesta terapéutica. Nefrologia. 2020;40(3):213-216 [doi]  

Neonatología

  1. Rodríguez-Blanco N, et al. Revisión exploratoria sobre series de casos de coronavirus (SARS-CoV, MERS-CoV y SARS-CoV-2) y sus resultados obstétricos y neonatales. Rev Esp Quimioter. 2020 Oct;33(5):313-326 [doi

Neumología

  1. Pascual-Guàrdia S, et al. Absence of Relevant Clinical Effects of SARS-COV-2 on the Affinity of Hemoglobin for O2 in Patients with COVID-19. Arch Bronconeumol (Engl Ed). 2021 Mar 26:S0300-2896(21)00113-7 [doi
  2. González-Gay MA, et al. Biologic Therapy in COVID-19. Arch Bronconeumol. 2021 Jan;57 Suppl 1:1-2 [doi
  3. Figueira Gonçalves JM, et al. Biomarkers of acute respiratory distress syndrome in adults hospitalised for severe SARS-CoV-2 infection in Tenerife Island, Spain. BMC Res Notes. 2020 Dec 9;13(1):555 [doi]
  4. Graziani D, et al. Characteristics and Prognosis of COVID-19 in Patients with COPD. J Clin Med. 2020 Oct 12;9(10):3259 [doi
  5. Jiménez-Ruiz CA, et al. COVID-19 and Smoking: A Systematic Review and Meta-Analysis of the Evidence. Arch Bronconeumol. 2021 Jan;57 Suppl 1:21-34 [doi
  6. Segura Alba O, et al. Dispositivo de oxigenación con reservorio y PEEP (DORPEEP) en pacientes con dificultad respiratoria aguda por COVID-19 [texto completo]. Med Clin (Barc). 2020;S0025-7753(20)30260-8 [doi]
  7. Farré R, et al. Emergency Mechanical Ventilators for Covid-19. Arch Bronconeumol. 2020 Jul;56 Suppl 2:7-8 [doi
  8. Del Campo F, et al. Estudio de la adherencia al tratamiento con presión continua positiva en la vía aérea en pacientes con síndrome de apnea obstructiva del sueño en el confinamiento impuesto durante la pandemia de COVID-19. Arch Bronconeumol. 2020 Jul 16;S0300-2896(20)30222-2 [doi]
  9. Ramos Hernández C, et al. Lung Ultrasound to Predict Unfavorable Progress in Patients Hospitalized for COVID-19. Arch Bronconeumol. 2021 Jan;57 Suppl 1:47-54 [doi
  10. Angulo M, ET AL.. Mechanical Risks of Ventilator Sharing in the COVID-19 Era: A Simulation-Based Study. Arch Bronconeumol. 2020 Nov;56(11):752-753 [doi
  11. Mateos-Rodríguez A, et al. Alternative CPAP methods for the treatment of secondary serious respiratory failure due to pneumonia by COVID-19. Med Clin (Barc). 2021 Jan 22;156(2):55-60 [doi]
  12. Díaz Lobato S, et al. ¿Podemos usar terapias respiratorias no invasivas en la pandemia COVID-19? Med Clin (Barc). 2020 Aug 28;155(4):183 [doi
  13. Gea J, et al. Posibles limitaciones en la utilización de la presión arterial de oxígeno en procesos respiratorios por SARS-CoV-2. Arch Bronconeumol. 2020;56 Suppl 2:9-10 [doi
  14. Rodriguez-Sevilla J, et al. Pulmonary Embolism in Patients With Covid-19 Pneumonia: The Utility of D-dimer. Arch Bronconeumol. 2020 Nov;56(11):758-759 [doi
  15. Pérez Pallarés J, et al. Recomendaciones de consenso SEPAR-AEER sobre la utilidad de la ecografía torácica en el manejo del paciente con sospecha o infección confirmada con COVID-19. Arch Bronconeumol. 2020;56 Suppl 2:27-30 [doi
  16. Martínez-Pizarro S. Rehabilitación respiratoria en pacientes con COVID-19 [texto completo]. Rehabilitacion (Madr). 2020 May 14;10.1016/j.rh.2020.04.002 [doi]
  17. Martín Raymondi D, et al. Supportive treatment of COVID 19 patients with mild respiratory failure in a primary hospital. Med Clin (Barc). 2020 Sep 11;155(5):222-223 [doi
  18. González-Gerez JJ, et al. Therapeutic pulmonary telerehabilitation protocol for patients affected by COVID-19, confined to their homes: study protocol for a randomized controlled trial. Trials. 2020;21(1):588 [doi
  19. López-Reyes R, et al. Thrombotic Risk and Covid-19: Review of Current Evidence for a Better Diagnostic and Therapeutic Approach. Arch Bronconeumol. 2021 Jan;57 Suppl 1:55-64 [doi
  20. Farré R, et al. Ventiladores mecánicos de emergencia para la COVID-19. Arch Bronconeumol. 2020;56 Suppl 2:7-8 [doi

Neurología

  1. Martín-Jiménez P, et al. Cognitive Impairment Is a Common Comorbidity in Deceased COVID-19 Patients: A Hospital-Based Retrospective Cohort Study. J Alzheimers Dis. 2020;78(4):1367-1372 [doi
  2. Abenza-Abildúa MJ, et al. Neurological complications in critical patients with COVID-19. Neurologia. 2020 Nov-Dec;35(9):621-627 [doi
  3. Fasano A, et al. Predictors of COVID-19 outcome in Parkinson’s disease. Parkinsonism Relat Disord. 2020 Sep;78:134-137 [doi
  4. Valero-López G, et al. Pulse immunosuppressive therapy for multiple sclerosis during the SARS-CoV-2 lockdown de-escalation plan: Safety algorithm. Neurologia. 2020 Jul-Aug;35(6):357-362 [doi]. Erratum in: Neurologia. 2020 Sep;35(7):541. Erratum in: Neurologia. 2020 Sep;35(7):541

Obstetricia y ginecología

  1. Martínez-Perez O, et al. Association Between Mode of Delivery Among Pregnant Women With COVID-19 and Maternal and Neonatal Outcomes in Spain. JAMA. 2020 Jul 21;324(3):296-299 [doi].  Erratum in: JAMA. 2020 Jul 21;324(3):305
  2. Gracia-Perez-Bonfils A, et al. Fetal heart rate changes on the cardiotocograph trace secondary to maternal COVID-19 infection. Eur J Obstet Gynecol Reprod Biol. 2020 Sep;252:286-293 [doi
  3. Valdés-Bango M, et al. Guía de actuación para el manejo de la infección por COVID-19 durante en el embarazo. Clin Invest Ginecol Obstet. 2020 Jul-Sep;47(3):118-127 [doi
  4. González R, et al. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial. Trials. 2020 Jul 2;21(1):607 [doi
  5. Ramírez I, et al. Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: Recommendations from the Spanish Menopause Society, Sociedad Española de Ginecología y Obstetricia and Sociedad Española de Trombosis y Hemostasia. Maturitas. 2020;137:57‐62 [doi]
  6. Rodríguez-Blanco N, et al. Revisión exploratoria sobre series de casos de coronavirus (SARS-CoV, MERS-CoV y SARS-CoV-2) y sus resultados obstétricos y neonatales. Rev Esp Quimioter. 2020 Oct;33(5):313-326 [doi
  7. Villalaín C, et al. Seroprevalence analysis of SARS-CoV-2 in pregnant women along the first pandemic outbreak and perinatal outcome. PLoS One. 2020 Nov 30;15(11):e0243029 [doi]

Oftalmología

  1. Fanlo P, et al. Impact of novel coronavirus infection in patients with uveitis associated with an autoimmune disease: result of the COVID-19-GEAS patient survey. Arch Soc Esp Oftalmol. 2021 Jan 23:S0365-6691(21)00022-8 [doi
  2. Millá Griñó E, et al. Therapeutic conflict in patients with COVID-19 and glaucoma. Med Clin (Barc). 2020 Aug 28;155(4):182 [doi

Oncología

  1. Kuderer NM, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907-1918 [doi
  2. Faura A, et al. Initial report on Spanish pediatric oncologic, hematologic, and post stem cell transplantation patients during SARS-CoV-2 pandemic. Pediatr Blood Cancer. 2020 Jul 16;e28557 [doi
  3. Lara Álvarez MÁ, et al. Mortalidad por covid-19 en pacientes con cáncer en un hospital de Madrid durante las primeras 3 semanas de epidemia. Med Clin (Barc). 2020;S0025-7753(20)30281-5 [doi
  4. Franco F, et al. Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel). Curr Oncol. 2021 Mar 16;28(2):1249-1255 [doi
  5. Pinato DJ, et al. Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe. Cancers (Basel). 2020 Jul 8;12(7):E1841 [doi
  6. Flamarique S, et al. Reirradiación con radioterapia estereotáxica corporal (SBRT) en recidiva irresecable de cáncer de cabeza y cuello: a propósito de un caso. An Sist Sanit Navar. 2019;42(3):339-343 [doi]

Pediatría

  1. Pérez-Martinez A, et al. Clinical outcome of SARS-CoV-2 infection in immunosuppressed children in Spain. Eur J Pediatr. 2021 Mar;180(3):967-971 [doi
  2. García-Salido A, et al. Documento español de consenso sobre diagnóstico, estabilización y tratamiento del síndrome inflamatorio multisistémico pediátrico vinculado a SARS-CoV-2 (SIM-PedS). An Pediatr (Barc). 2021 Feb;94(2):116.e1-116.e11 [doi
  3. Storch-de-Gracia P, et al. Espectro clínico y factores de riesgo de enfermedad complicada en niños ingresados con infección por SARS-CoV-2. An Pediatr (Barc). 2020 Nov;93(5):323-333 [doi
  4. Gimeno-Costa R, et al. Insuficiencia respiratoria COVID-19: soporte con ECMO para niños y adultos jóvenes. An Pediatr (Barc). 2020 Jun 11;S1695-4033(20)30188-0 [doi]
  5. González Cortés R, et al. A multicenter national survey of children with SARS-CoV-2 infection admitted to Spanish Pediatric Intensive Care Units. Intensive Care Med. 2020 Sep;46(9):1774-1776 [doi
  6. Moraleda C, et al. Multi-inflammatory Syndrome in Children Related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Spain. Clin Infect Dis. 2021 May 4;72(9):e397-e401 [doi]
  7. Moreno-Galarraga L, et al. SARS-CoV-2 infection in children requiring hospitalization: the experience of Navarra, Spain. World J Pediatr. 2020 Dec;16(6):614-622 [doi
  8. García-Salido A, et al. Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain. Crit Care. 2020 Nov 26;24(1):666 [doi]
  9. Velasco Puyó P, et al. Tocilizumab en niño con leucemia linfoblástica aguda y síndrome de liberación de citoquinas asociado a COVID-19. An Pediatr (Barc). 2020;93(2):132-133 [doi]  

Reumatología

  1. Garcia-Guillén A, et al. COVID-19: La visión del residente de reumatología. Reumatol Clin. 2020;S1699-258X(20)30134-0 [doi
  2. Fernandez-Gutierrez B. COVID-19 con afectación pulmonar. Una enfermedad autoinmune de causa conocida. Reumatol Clin. 2020;16(4):253-254 [doi
  3. Santos CS, et al. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease. Clin Rheumatol. 2020 Sep;39(9):2789-2796 [doi
  4. Michelena X, et al. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum. 2020 Aug;50(4):564-570 [doi
  5. Blanch-Rubió J, et al. Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions. Aging (Albany NY). 2020 Oct 20;12(20):19923-19937 [doi
  6. Pablos JL, et al. Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. Ann Rheum Dis. 2020 Sep;79(9):1170-1173 [doi
  7. Freites Nuñez DD, et al. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020 Nov;79(11):1393-1399 [doi

Trasplantes

  1. Cravedi P, et al. COVID-19 and Kidney Transplantation: Results from the TANGO International Transplant Consortium. Am J Transplant. 2020 Nov;20(11):3140-3148 [doi]
  2. González J, et al. Early experience with COVID-19 in kidney transplantation recipients: update and review. Int Braz J Urol. 2020;46(suppl.1):145-155 [doi
  3. González J, et al. Early experience with COVID-19 in kidney transplantation recipients: update and review. Int Braz J Urol. 2020;46(suppl.1):145-155 [doi
  4. Colmenero J, et al. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. J Hepatol. 2021 Jan;74(1):148-155 [doi
  5. Forns X, et al. Inmunosupresión en el trasplante hepático en la era covid-19. Gastroenterol Hepatol. 2020 Jun 12;S0210-5705(20)30215-6 [doi]
  6. Sánchez Cadena AD, et al. Inmunoglobulinas por vía intravenosa: una alternativa terapéutica a tener en cuenta en el paciente trasplantado renal con COVID-19. Nefrologia. 2020;S0211-6995(20)30065-5 [doi
  7. Forns X, et al. Liver transplant immunosuppression during the covid-19 pandemic. Gastroenterol Hepatol. 2020 Oct;43(8):457-463 [doi
  8. Montagud-Marrahi E, et al. Preliminary data on outcomes of SARS-CoV-2 infection in a Spanish single center cohort of kidney recipients. Am J Transplant. 2020 Oct;20(10):2958-2959 [doi
  9. Crespo M, et al. Respiratory and Gastrointestinal COVID-19 Phenotypes in Kidney Transplant Recipients. Transplantation. 2020 Nov;104(11):2225-2233 [doi
  10. Trujillo H, et al. Tocilizumab use in Kidney Transplant Patients with COVID-19. Clin Transplant. 2020 Nov;34(11):e14072 [doi
  11. Loinaz C, et al. Varied clinical presentation and outcome of SARS-CoV-2 infection in liver transplant recipients: Initial experience at a single center in Madrid, Spain. Transpl Infect Dis. 2020 Oct;22(5):e13372 [doi

Tratamientos. Anakinra

  1. Figuero-Pérez L, et al. Anakinra, una alternativa potencial en el tratamiento de la infección respiratoria grave por SARS-CoV-2 refractaria a tocilizumab. Reumatol Clin. 2020;S1699-258X(20)30142-X [doi
  2. Muñoz-Jiménez A, et al. Propuesta de uso de anakinra en el distrés respiratorio agudo secundario a COVID-19. Reumatol Clin. 2021 Jun-Jul;17(6):309-312 [doi]

Tratamientos. Antibióticos

  1. Gonzalez-Zorn B. Antibiotic use in the COVID-19 crisis in Spain. Clin Microbiol Infect. 2021 Apr;27(4):646-647 [doi
  2. Rodríguez-Molinero A, et al. Observational study of azithromycin in hospitalized patients with COVID-19. PLoS One. 2020 Sep 3;15(9):e0238681 [doi

Tratamientos. Anticoagulantes

  1. Ayerbe L, et al. The association between treatment with heparin and survival in patients with Covid-19 [texto completo]. J Thromb Thrombolysis. 2020 May 31;1‐4 [doi]

Tratamientos. Antimaláricos

  1. Ayerbe L, et al. The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients. Intern Emerg Med. 2020 Nov;15(8):1501-1506 [doi
  2. Guisado-Vasco P, et al. Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort). EClinicalMedicine. 2020 Nov;28:100591 [doi
  3. Mitjà O, et al. A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. N Engl J Med. 2021 Feb 4;384(5):417-427 [doi
  4. Cuadrado-Lavín A, et al. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Jun 3;21(1):472 [doi]
  5. Santillán García A, et al. Evidencia viva como respuesta a las controversias en el uso de antimaláricos en COVID-19. Rev Esp Cardiol. 2020;73(8):693-694 [doi]
  6. Cairoli E, et al. Hidroxicloroquina en el tratamiento del COVID-19: como utilizarla a la espera de evidencia científica concluyente. Med Clin (Barc). 2020 Aug 14;155(3):134-135 [doi]
  7. Velasco-González V, et al. Hydroxychloroquine and Potential Drug Interactions in Older Adults. Arch Bronconeumol (Engl Ed). 2020 Oct;56(10):679-681 [doi
  8. González R, et al. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial. Trials. 2020 Jul 2;21(1):607 [doi
  9. Mitjà O, et al. Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial. Clin Infect Dis. 2020 Jul 16;ciaa1009 [doi
  10. Vivanco-Hidalgo RM, et al. Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine: results from a population-based prospective cohort in Catalonia, Spain, 2020. Euro Surveill. 2021 Mar;26(9) [doi
  11. Tejada Cifuentes F, et al. Incidence of COVID-19 in patients under chronic treatment with hydroxychloroquine. Med Clin (Barc). 2021 Feb 26;156(4):166-171 [doi
  12. Laplana M, et al. Lack of protective effect of chloroquine derivatives on COVID-19 disease in a Spanish sample of chronically treated patients. PLoS One. 2020 Dec 14;15(12):e0243598 [doi
  13. Rodriguez-Valero N, et al. Malaria prophylaxis approach during COVID-19 pandemic. Travel Med Infect Dis. 2020 Apr 29;101716 [doi]
  14. Grau-Pujol B, et al. Pre-exposure prophylaxis with hydroxychloroquine for high-risk healthcare workers during the COVID-19 pandemic: A structured summary of a study protocol for a multicentre, double-blind randomized controlled trial. Trials. 2020 Jul 29;21(1):688 [doi]
  15. Guzman-Prado Y. Recent Findings on Cardiovascular Safety With the Use of Chloroquine and Hydroxychloroquine for COVID-19. Am J Cardiol. 2020 Jun 9;S0002-9149(20)30559-2 [doi
  16. Mayayo-Vicente S, et al. Tratamiento farmacológico en tiempos de incertidumbre: uso de la hidroxicloroquina/cloroquina en el tratamiento de COVID-19. Semergen. 2020 Aug;46 Suppl 1:20-27 [doi]
  17. Lasheras I, et al. Uso de antipalúdicos en el tratamiento del COVID-19: ¿una ventana de oportunidad? [texto completo]. Med Clin (Barc). 2020 Apr 22;S0025-7753(20)30244-X [doi]

Tratamientos. Antireceptores de interleucina-6

  1. León López R, et al. Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial. BMJ Open. 2020 Nov 14;10(11):e039951 [doi]
  2. Caballero Bermejo AF, et al. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Sep 16;21(1):794 [doi] https://doi.org/10.1186/s13063-020-04633-3
  3. Garcia-Vicuña R, et al. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Sep 9;21(1):772 [doi

Tratamientos. Antiséticos orales

  1. Palop Larrea V, et al. Utilización de antisépticos orales para la infección por SARS-CoV-2. Med Clin (Barc). 2020 Nov 13;155(9):416-417 [doi

Tratamientos. Antivirales

  1. Guisado-Vasco P, et al. Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort). EClinicalMedicine. 2020 Nov;28:100591 [doi
  2. Méndez-Echevarría A, et al. Compassionate use of remdesivir in children with COVID-19. Eur J Pediatr. 2021 Apr;180(4):1317-1322 [doi]
  3. Estella Á, et al. Del empirismo a la evidencia científica en el tratamiento con antivíricos en los casos graves de infección por coronavirus en tiempos de epidemia. Med Intensiva. 2020 Nov;44(8):509-512 [doi
  4. Benlloch JM, et al. Effect of the early use of antivirals on the COVID-19 pandemic. A computational network modeling approach. Chaos Solitons Fractals. 2020 Nov;140:110168 [doi
  5. Macías J, et al. High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment. Sci Rep. 2020 Dec 1;10(1):20958 [doi
  6. Soriano A, et al. Impact of Remdesivir on the Treatment of COVID-19 During the First Wave in Spain. Adv Ther. 2021 Jun 12:1–13 [doi
  7. Brandáriz Núñez D, et al. Interacciones medicamentosas potenciales en pacientes COVID 19 en tratamiento con lopinavir/ritonavir. Med Clin (Barc). 2020 jul 9;S0025-7753(20)30450-4 [doi]
  8. Brandáriz Núñez D, et al. Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir. Med Clin (Barc). 2020 Oct 9;155(7):281-287 [doi
  9. Garcia-Vidal C, et al. Real-life use of remdesivir in hospitalized patients with COVID-19. Rev Esp Quimioter. 2021 Apr;34(2):136-140 [doi
  10. Reina J. Remdesivir, la esperanza antiviral frente al SARS-CoV-2 [texto completo]. Rev Esp Quimioter. 2020 Jun;33(3):176-179 [doi]

Tratamientos. Cannabis

  1. Pascual Pastor F, et al. Cannabis terapéutico y COVID-19: entre el oportunismo y la infoxicación. Adicciones. 2020 Jul 1;32(3):167-172 [doi

Tratamientos. Células madre

  1. Soler Rich R, et al. Abordaje terapéutico del SARS-CoV-2 (COVID-19) mediante células mesenquimales de médula ósea alogénica expandidas. Conceptos a propósito de un primer caso en España. Med Clin (Barc). 2020 Jul 3;S0025-7753(20)30407-3 [doi
  2. Soler Rich R, et al. Expanded Mesenchymal Stem Cells: a novel therapeutic approach of SARS-CoV-2 pneumonia (COVID-19). Concepts regarding a first case in Spain. Med Clin (Barc). 2020 Oct 9;155(7):318-319 [doi
  3. Piñana JL, et al. Seasonal human coronaviruses respiratory tract infection in recipients of allogeneic hematopoietic stem cell transplantation. J Infect Dis. 2020 Aug 29:jiaa553 [doi

Tratamientos. Ciclosporina

  1. Sanchez-Pernaute O, et al. Why Choose Cyclosporin A as First-line Therapy in COVID-19 Pneumonia [texto completo]. Reumatol Clin. 2020 Apr 16;S1699-258X(20)30044-9 [doi]

Tratamiento. Corticosteroides

  1. Rodríguez-Molinero A, et al. Association between high-dose steroid therapy, respiratory function, and time to discharge in patients with COVID-19: Cohort study. Med Clin (Barc). 2021 Jan 8;156(1):7-12 [doi
  2. Guisado-Vasco P, et al. Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort). EClinicalMedicine. 2020 Nov;28:100591 [doi
  3. González-Castro A, et al. Combined therapy of tocilizumab and corticosteroids in severe SARS-CoV-2 disease. Med Intensiva (Engl Ed). 2021 Mar 18:S0210-5691(21)00039-5 [doi
  4. Ruiz-Antorán B, et al. Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study. Infect Dis Ther. 2021 Mar;10(1):347-362 [doi]
  5. Ruiz-Antorán B, et al. A Response to: Letter to the Editor Regarding Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort. Infect Dis Ther. 2021 Apr 29:1–3 [doi
  6. Cusacovich I, et al. Corticosteroid Pulses for Hospitalized Patients with COVID-19: Effects on Mortality. Mediators Inflamm. 2021 Mar 12;2021:6637227 [doi
  7. Van den Eynde E, et al. Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital. Infect Dis (Lond). 2021 Feb 23:1-12 [doi
  8. Johnson RM, et al. Dexamethasone in the management of covid -19. BMJ. 2020 Jul 3;370:m2648 [doi
  9. Callejas Rubio JL, et al. Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection. Med Clin (Barc). 2020 Aug 28;155(4):159-161 [doi
  10. Aomar-Millán IF, et al. Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation. Med Clin (Barc). 2021 Jan 28:S0025-7753(21)00026-9 [doi
  11. González-Castro A, et al. Impact of corticosteroid therapy on the survival of critical COVID-19 patients admitted into an intensive care unit. Rev Esp Anestesiol Reanim. 2021 Mar 8:S0034-9356(21)00096-7 [doi
  12. Fernández Cruz A, et al. Impact of glucocorticoid treatment in sars-cov-2 infection mortality: a retrospective controlled cohort study. Antimicrob Agents Chemother. 2020;AAC.01168-20 [doi
  13. Blasco Patiño F, et al. Indication of glucocorticoid pulses for patients with SARS-CoV-2 infection. Med Clin (Barc). 2021 Apr 9;156(7):360 [doi
  14. Sanz Herrero F, et al. Methylprednisolone added to tocilizumab reduces mortality in SARS-CoV-2 pneumonia: An observational study. J Intern Med. 2021 Feb;289(2):259-263 [doi]
  15. Saiz-Rodríguez M, et al. Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial. Trials. 2020 Jul 9;21(1):632 [doi
  16. Fernández-Cruz A, et al. A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality. Antimicrob Agents Chemother. 2020 Aug 20;64(9):e01168-20 [doi
  17. Ruiz-Irastorza G, et al. Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: An observational comparative study using routine care data. PLoS One. 2020 Sep 22;15(9):e0239401 [doi
  18. Jiménez-Brítez G, et al. Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience. Med Clin (Barc). 2020 Nov 13;155(9):410-411 [doi
  19. Rodríguez-Baño J, et al. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19). Clin Microbiol Infect. 2021 Feb;27(2):244-252 [doi
  20. Corral-Gudino L, et al. Unresolved questions about the treatment of COVID-19 with corticosteroids. Med Clin (Barc). 2021 Feb 12;156(3):143-144 [doi
Tratamientos. Diuréticos
 
  1. Brennecke A, et al. Is Inhaled Furosemide a Potential Therapeutic for COVID-19? Am J Med Sci. 2020 Jun 1;S0002-9629(20)30238-X [doi

Tratamientos. Estatinas

  1. Torres-Peña JD, et al. Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry. Drugs. 2021 Apr;81(6):685-695 [doi

Tratamientos. Inhibidores de la JAK-kinasa

  1. Gutiérrez-Lorenzo M, et al. Baricitinib en el tratamiento de infección por SARS-CoV-2. Rev Esp Quimioter. 2020 Aug;33(4):294-295 [doi
  2. Jovani V, et al. Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors. Ann Rheum Dis. 2020 Jun 25:annrheumdis-2020-218152 [doi

Tratamientos. Inhibidores del sistema renina-angiotensina-aldosterona

  1. Martínez-Del Río J, et al. Comparative analysis between the use of renin-angiotensin system antagonists and clinical outcomes of hospitalized patients with COVID-19 respiratory infection. Med Clin (Barc). 2020 Dec 11;155(11):473-481 [doi
  2. Soria Arcos F, et al. Controversias sobre el tratamiento con IECA/ARA-II y COVID-19. Rev Esp Cardiol (Engl Ed). 2020;73(6):516 [doi]
  3. López-Otero D, et al. Impacto de los inhibidores de la enzima de conversión de la angiotensina y los antagonistas del receptor de la angiotensina II en la COVID-19 en una población occidental. Registro CARDIOVID. Rev Esp Cardiol (Engl Ed). 2021 Feb;74(2):175-182 [doi]
  4. Usman MS, et al. A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 [published online ahead of print, 2020 Jun 2]. Am J Cardiol. 2020 Jun 2;S0002-9149(20)30548-8 [doi
  5. Amat-Santos IJ, et al. Ramipril in High Risk Patients with COVID-19 [texto completo]. J Am Coll Cardiol. 2020 May 22;S0735-1097(20)35395-X [doi]
  6. Quinn KL, et al. Renin-angiotensin-aldosterone system inhibitors and COVID-19. CMAJ. 2020;192(20):E553-E554 [doi
  7. Morales DR, et al. Renin-angiotensin system blockers and susceptibility to COVID-19: a multinational open science cohort study. medRxiv [Preprint]. 2020 Jun 12:2020.06.11.20125849 [doi
  8. Núñez-Gil IJ, et al. Renin-angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: Final analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry. Am Heart J. 2021 Jul;237:104-115 [doi
  9. Golpe R, et al. Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors. Med Clin (Barc). 2020 Dec 11;155(11):488-490 [doi
  10. Lamas-Barreiro JM, et al. Supresión de angiotensina II en la infección por el virus SARS-CoV-2: una propuesta terapéutica [texto completo]. Nefrologia. 2020 Apr 30;S0211-6995(20)30044-8 [doi]
  11. Vila-Corcoles A, et al. Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: A population-based cohort study in Southern Catalonia, Spain. J Clin Hypertens (Greenwich). 2020 Aug;22(8):1379-1388 [doi
  12. De Abajo FJ, et al. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study [texto completo]. Lancet. 2020 May 30;395(10238):1705-1714 [doi]

Tratamientos. Ivermectina

  1. López Reboiro ML, et al. Réplica: Ivermectina en COVID-19. ¿Argumentum ad ignorantiam? Rev Clin Esp. 2020 Jul 4;S0014-2565(20)30197-1 [doi
  2. Chaccour C, et al. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial. Trials. 2020;21(1):498 [doi

Tratamientos. Melatonina

  1. Acuña-Castroviejo D, et al. Clinical trial to test the efficacy of melatonin in COVID-19. J Pineal Res.2020 Oct;69(3):e12683 [doi
  2. Domínguez-Rodríguez A, et al. Melatonina, coronavirus, enfermedad cardiovascular y emergencia geriátrica: ¡usemos todo lo que tenemos! Rev Esp Cardiol. 2020 Dec;73(12):1081-1082 [doi
  3. García-Blas S, et al. Melatonina, coronavirus, enfermedad cardiovascular y emergencia geriátrica: ¡usemos todo lo que tenemos! Respuesta. Rev Esp Cardiol (Engl Ed). 2020 Dec;73(12):1082 [doi
  4. Rodríguez-Rubio M, et al. A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial. Trials. 2020 Aug 5;21(1):699 [doi
  5. García IG, et al. A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Jun 3;21(1):466 [doi]

Tratamientos. Oxígeno

  1. Segura Alba O, et al. Dispositivo de oxigenación con reservorio y PEEP (DORPEEP) en pacientes con dificultad respiratoria aguda por COVID-19. Med Clin (Barc). 2020 Aug 14;155(3):133-134 [doi
  2. González-Castro A, et al. The need for rigorous analysis of the effectiveness and efficiency of high flow oxygen therapy during the SARS-CoV-2 pandemic. Med Intensiva (Engl Ed). 2021 Mar 8:S0210-5691(21)00028-0 [doi
  3. Chiner E, et al. Pressure ulcers due to high-flow nasal cannula oxygen therapy in a patient with SARS-CoV-2 infection. Arch Bronconeumol. 2021 Apr;57 Suppl 2:44 [doi
  4. Belenguer-Muncharaz A, et al. Reply to «Pulmonary toxicity by oxygen and COVID-19». Med Intensiva. 2021 Jun 3:S0210-5691(21)00114-5 [doi

Tratamientos. Plasma de convalenciente

  1. Zeng QL, et al. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019. J Infect Dis. 2020;222(1):38-43 [doi

Tratamientos. Reacciones adversas

  1. Herrera-Lasso Regás V, et al. Reacciones adversas a fármacos utilizados en el tratamiento específico de la infección por SARS-CoV-2. Med Clin (Barc). 2020 Nov 27;155(10):448-453 [doi
  2. Novo de Matos J, et al. Síndrome de DRESS simulando enfermedad por coronavirus 2019-NcoV. Semergen. 2020;S1138-3593(20)30173-8 [doi]

Tratamientos. Rehabilitación

  1. Martínez-Pizarro S. Rehabilitación respiratoria en pacientes con COVID-19. Rehabilitacion (Madr). 2020 Oct-Dec;54(4):296-297 [doi

Tratamientos. Tocilizumab

  1. Guisado-Vasco P, et al. Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort). EClinicalMedicine. 2020 Nov;28:100591 [doi
  2. González-Castro A, et al. Combined therapy of tocilizumab and corticosteroids in severe SARS-CoV-2 disease. Med Intensiva (Engl Ed). 2021 Mar 18:S0210-5691(21)00039-5 [doi
  3. Ruiz-Antorán B, et al. Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study. Infect Dis Ther. 2021 Mar;10(1):347-362 [doi]
  4. Ruiz-Antorán B, et al. A Response to: Letter to the Editor Regarding Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort. Infect Dis Ther. 2021 Apr 29:1–3 [doi
  5. Van den Eynde E, et al. Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital. Infect Dis (Lond). 2021 Feb 23:1-12 [doi
  6. Cardona-Pascual I, et al. Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia. Med Clin (Barc). 2021 May 6:S0025-7753(21)00210-4 [doi
  7. Martínez-Sanz J, et al. Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study. Clin Microbiol Infect. 2021 Feb;27(2):238-243 [doi
  8. Moreno-Pérez O, et al. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study. J Autoimmun. 2020 Nov;114:102523 [doi
  9. Aomar-Millán IF, et al. Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation. Med Clin (Barc). 2021 Jan 28:S0025-7753(21)00026-9 [doi
  10. Masiá M, et al. Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study. EBioMedicine. 2020 Oct;60:102999 [doi
  11. Sanz Herrero F, et al. Methylprednisolone added to tocilizumab reduces mortality in SARS-CoV-2 pneumonia: An observational study. J Intern Med. 2021 Feb;289(2):259-263 [doi]
  12. Jiménez-Lozano I, et al. Safety of tocilizumab in COVID-19 pregnant women and their newborn: A retrospective study. J Clin Pharm Ther. 2021 Feb 26 [doi].
  13. Velasco Puyó P, et al. Tocilizumab en niño con leucemia linfoblástica aguda y síndrome de liberación de citoquinas asociado a COVID-19. An Pediatr (Barc). 2020 Jun 9;S1695-4033(20)30180-6 [doi
  14. Jiménez-Brítez G, et al. Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience. Med Clin (Barc). 2020 Nov 13;155(9):410-411 [doi
  15. Rodríguez-Baño J, et al. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19). Clin Microbiol Infect. 2021 Feb;27(2):244-252 [doi

Tratamientos. Vitamina D

  1. Entrenas Castillo M, et al. Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study. J Steroid Biochem Mol Biol. 2020 Oct;203:105751 [doi
  2. Quesada Gómez JM, et al. Vitamin D Receptor stimulation to reduce Acute Respiratory Distress Syndrome (ARDS) in patients with Coronavirus SARS-CoV-2 infections: Revised Ms SBMB 2020_166. J Steroid Biochem Mol Biol. 2020 Jun 11;105719 [doi]
  3. Tarazona-Santabalbina FJ, et al. VitaminD supplementation for the prevention and treatment of COVID-19: a position statement from the Spanish Society of Geriatrics and Gerontology. Rev Esp Geriatr Gerontol. 2021 Feb 8:S0211-139X(21)00004-4 [doi

Urgencias

  1. Miró Ò, et al. A case-control emergency department-based analysis of acute pancreatitis in Covid-19: Results of the UMC-19-S6. J Hepatobiliary Pancreat Sci. 2020 Dec 1:10.1002/jhbp.873 [doi] .
  2. Martín-Sánchez FJ, et al. Clinical presentation and outcome across age categories among patients with COVID-19 admitted to a Spanish Emergency Department [published online ahead of print, 2020 Jul 16]. Eur Geriatr Med. 2020 Jul 16;1-13 [doi]
  3. Gil-Rodrigo A, et al. Evaluación de las características clínicas y evolución de pacientes con COVID-19 a partir de una serie de 1000 pacientes atendidos en servicios de urgencias españoles. Emergencias. 2020;32(4):233-241
  4. Fragiel M, et al. Incidence, clinical, risk factors and outcomes of Guillain-Barré in Covid-19. Ann Neurol. 2021 Mar;89(3):598-603 [doi]